The U.S. Food and Drug Administration is alerting patients and health care professionals that some EpiPen and EpiPen Jr. auto injectors — including their authorized generic versions — may not easily slide out of their carrier tubes. That could delay or prevent use of the device during an allergy emergency.

The advisory follows a letter dated Nov. 1 to pharmacists and other health care professionals from Pfizer — which makes EpiPens for Cecil-based drugmaker Mylan — alerting them to the problem.

Pfizer said that “in a very small number of cases” the labels weren’t applied properly and they could become stuck to the inside of the carrier tube.

Users “may not be able to quickly remove the epinephrine auto-injector from the carrier tube,” the FDA said.

Advertise with us

The agency urged patients and caregivers to inspect their EpiPens to make sure they can be removed quickly.

Pharmacists should inspect the auto-injectors and avoid dispensing them if they don’t easily slide out of the tube, the agency said.

Patients should contact Mylan customer relations at 800-796-9526 with any questions, or if the devices don’t readily slide out of the tube, or if the label is not fully adhered to the auto-injector, Pfizer said.

The warning is the latest setback for the EpiPen, whose sales have been declining amid a backlash over huge price increases, growing competition and manufacturing issues that have led to supply problems and customer shortages this year.

Sales likely will soon take another hit. Rival drugmaker Teva Pharmaceutical Industries last week said it expects to launch its recently approved generic version of the EpiPen before year-end.

Advertise with us

On Monday, Mylan said that lower sales of the EpiPen contributed to a 14 percent slump in sales in the company’s North America segment in the third quarter.

That dragged down Mylan’s overall revenues for the third quarter to $2.86 billion, down 4 percent from the same quarter a year ago.

Despite the decline, Mylan said profits for the three months ended Sept. 30 doubled to $176.7 million, or 34 cents per share.

Excluding special items, adjusted profits were up 10 percent to $648 million, while earnings per share rose 14 percent to $1.25, beating the consensus estimate on Wall Street of $1.19.

In the second quarter, Mylan announced that its board was conducting a strategic review aimed at “unlocking the true value” of the company. Possible moves could include a sale or merger, spinning off one or more businesses, or taking the company private.

Advertise with us

CEO Heather Bresch said Monday that it was too early to discuss the review.

“I can assure you the board is busy looking at lots of things,” she said in a conference call with analysts. “When they’re ready for an update, we certainly will put that out. But we put no timeframes around that.”

Mylan released its financial results after the close of the stock market Monday.

The company’s shares — which are off 26 percent since the beginning of the year — lost 31 cents Monday to close at $31.37.

Shares rose in after hours trading.

Advertise with us

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.

Updated at 6:30 p.m. Nov. 5, 2018